Kidney Cancer Clinical Trial

Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

Summary

This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of cancer cells. Combination therapy with atezolizumab and cabozantinib may shrink the cancer and allow a longer survival time in patients with metastatic renal cell carcinoma.

View Full Description

Full Description

PRIMARY OBJECTIVE:

I. To compare progression-free survival in participants with metastatic papillary renal cell carcinoma (mPRCC) randomized to cabozantinib S-malate (cabozantinib) with atezolizumab versus cabozantinib alone.

SECONDARY OBJECTIVES:

I. To compare overall survival in participants with mPRCC randomized to cabozantinib with atezolizumab versus cabozantinib alone.

II. To compare Response Evaluation Criteria in Solid Tumors (RECIST) objective response rate (confirmed and unconfirmed, complete and partial response) in participants with mPRCC randomized to cabozantinib with atezolizumab versus cabozantinib alone.

III. To evaluate the quantitative and qualitive adverse events observed in each treatment arm.

BANKING OBJECTIVE:

I. To bank biospecimens for future correlative studies.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive cabozantinib S-malate orally (PO) once daily (QD) on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) and bone scans throughout the trial. Patients may also undergo collection of blood samples throughout the trial.

ARM II: Patients receive cabozantinib S-malate PO QD on days 1-21 and atezolizumab intravenously (IV) over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and bone scans throughout the trial. Patients may also undergo collection of blood samples throughout the trial.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for up to 5 years.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participants must have a histologically confirmed diagnosis of metastatic papillary renal cell carcinoma (PRCC), either type 1 or type 2. (NOTE: A designation of type 1 or type 2 should be made by the local pathologist if possible but is not required). Mixed histologies which contain type 1 or type 2 along with any other RCC histology/histologies will be allowed provided that they contain a papillary component
Participants must have measurable disease per RECIST 1.1 criteria. All measurable lesions must be assessed by CT or magnetic resonance imaging (MRI) within 28 days prior to registration. All non-measurable lesions must be assessed by CT or MRI, or nuclear medicine bone scan within 42 days prior to registration. The CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality. If there is clinical suspicion for bone metastases at the time of enrollment (at the discretion of the investigator), bone scan must be performed at baseline (within 42 days prior to registration)
Participants with new or progressive brain metastases (active brain metastases) must not require immediate central nervous system (CNS) specific treatment at the time of study registration or anticipated during the first cycle of therapy. Patients with leptomeningeal disease are excluded from enrolling
Participants with measurable disease, per RECIST version (v)1.1, must be present outside the CNS
Participants must have no history of intracranial hemorrhage or spinal cord hemorrhage
Participants, if needed, must receive a stable dose of anti-convulsant therapy
Participants must complete all prior radiation therapy at least 14 days prior to registration. Participants must have recovered to =< grade 1 from all associated toxicities at the time of registration unless the toxicity is determined to be not clinically significant by the registering investigator
Participants must be >= 18 years of age
Participants must have a complete physical examination and medical history within 28 days prior to registration
Participants must have a Zubrod performance status of 0-2
White blood count (WBC) >= 2 x 10^3/uL (within 28 days prior to registration)
Absolute neutrophil count (ANC) >= 1.5 x 10^3/uL (within 28 days prior to registration)
Platelet count >= 100 x 10^3/uL (within 28 days prior to registration)
Lymphocyte count >= 0.5 x 10^3/uL (within 28 days prior to registration)
Hemoglobin (>= 9 g/dL) (within 28 days prior to registration). Participants may be transfused to meet this criterion
Total serum bilirubin =< 1.5 x the institutional upper limit of normal (ULN) unless history of Gilbert's disease (within 28 days prior to registration). Participants with history of Gilbert's disease must have total bilirubin =< 5 x institutional ULN
Aspartate aminotransferase (AST) must be =< 3 x the institutional ULN unless the liver is involved with the tumor, in which case serum transaminase (SGOT) must be =< 5 x the institutional ULN (within 28 days prior to registration)
Alanine aminotransferase (ALT), must be =< 3 x the institutional ULN unless the liver is involved with the tumor, in which case serum transaminase (SGPT) must be =< 5 x the institutional ULN (within 28 days prior to registration)
Participants must have serum creatinine =< 2 x the institutional ULN OR creatinine clearance (either measured or calculated) > 30 mL/min and obtained within 28 days prior to registration
Participants must have urine protein < 3+ within 28 days prior to registration. If urine protein is 3+ or greater, then urine protein by 24-hour collection must show less than 3 grams of protein
Participants must have documented blood pressure of systolic blood pressure (SBP) < 150 mm Hg or diastolic blood pressure (DBP) < 100 mm Hg within 14 days prior to registration
Participants with known human immunodeficiency virus (HIV) must be on effective anti-retroviral therapy at registration and have undetectable viral load within 6 months of registration
Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load while on suppressive therapy within 6 months prior to registration, if indicated
Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants currently being treated for HCV infection must have undetectable HCV viral load within 6 months prior to registration
Participants must be able to take oral medications (i.e., swallow pills whole). Participants must not have gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures that could in the opinion of the treating investigator affect absorption, or active peptic ulcer disease. Participants with intractable nausea or vomiting are not eligible
Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System

Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines

NOTE: For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
As a part of the OPEN registration process for OPEN access instructions) the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system

Exclusion Criteria:

Participants must not have undergone stereotactic radiotherapy within 7 days prior to initiation of study treatment, whole-brain radiotherapy within 14 days prior to initiation of study treatment, or neurosurgical resection within 28 days prior to initiation of study treatment
Participants must not have ongoing requirements for corticosteroids as therapy for CNS disease
Participants must not have cavitating pulmonary lesions
Participants must not have uncontrolled pleural effusions, pericardial effusions, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Participants with indwelling catheters (e.g., PleurX) are allowed
Participants must not have tumor invading the gastrointestinal (GI) tract or evidence of endotracheal or endobronchial tumor within 28 days prior to registration
Participants must not have evidence of tumor invading or encasing any major blood vessels
Participants must not have had major surgery within 28 days prior to registration, and participants must have recovered from any adverse effects of surgery
Participants must not have had prior treatment with cabozantinib for any reason
Participants must not have had prior treatment or adjuvant therapy with PD-1/PD-L1 checkpoint inhibitors for any reason within the past 6 months
Participants must not have received more than one prior systemic therapy for advanced or metastatic renal cell carcinoma with the exception of another VEGF inhibitor Food and Drug Administration (FDA)-approved for advanced RCC (i.e., pazopanib, bevacizumab, sorafenib or axitinib). If a participant develops metastatic disease within six months of discontinuation of adjuvant therapy, this will constitute one prior systemic therapy for advanced or metastatic RCC. If a patient develops metastatic disease and more than six months has elapsed since discontinuation of adjuvant therapy, this will not constitute prior systemic therapy for advanced or metastatic RCC
Participants must not take within 14 days prior to registration, nor plan to take while on protocol treatment, any strong CYP3A4 inhibitors (e.g. boceprevir, cobicistat, danoprevir, elvitegravir/RIT, fluvoxamine, indinavir, itraconazole, ketoconazole, lopinavir/RIT, nefazodone, nelfinavir, posaconazole, ritonavir, telaprevir, telithromycin, tipranavir/RIT, or voriconazole,); Please refer to https://drug-interactions.medicine.iu.edu/MainTable.aspx for the updated CYP3A4 inhibitors or inducers
Participants must not take within 14 days prior to registration, nor plan to take while on protocol treatment, any strong CYP3A4 inducers (e.g. avasimibe, phenytoin, rifampin, rifabutin); Please refer to https://drug-interactions.medicine.iu.edu/MainTable.aspx for the updated CYP3A4 inhibitors or inducers
Participants must not be receiving or planning to receive any other investigational agents at time of registration
Participants must not have been diagnosed with a clinically significant autoimmune disease, exceptions such as diabetes, eczema, and vitiligo are allowed. Other non-clinically significant autoimmune diseases are allowed if approved by the registering investigator
Participants must not be on steroid doses > 10 mg prednisone equivalent. Replacement steroid doses for adrenal insufficiency will be allowed. Also, short duration steroid therapy to prevent allergic reactions are acceptable (e.g. prior to CT imaging)
Participants must not have any clinical evidence of congestive heart failure (CHF) (specifically, New York Heart Association [NYHA] class III [moderate] or class IV [severe]) at the time of registration
Participants must not have known history of congenital long QT syndrome and must not have experienced unstable angina pectoris, clinically significant cardiac arrhythmias, or stroke (transient ischemic attack [TIA] or other ischemic event) within 90 days prior to registration
Participants must not have experienced myocardial infarction or thromboembolic event requiring anticoagulation within 90 days of registration, unless clinically stable with ongoing medical management
Participants must not have had any clinically-significant GI bleeding within 3 months prior to registration and participants must not have a GI disorder which (at the discretion of the investigator) bears a high risk of perforation or fistula (e.g. Crohn's disease)
Participants must not have had hemoptysis of >= (2.5 mL) of red blood, and do not demonstrate any other signs indicative of pulmonary hemorrhage within 3 months prior registration
Participants must not be pregnant or nursing, due to VEGF therapy being toxic to embryogenesis. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
Participants must not be on warfarin, at therapeutic doses. Low dose aspirin for cardio-protection (per local applicable guidelines) and low molecular weight heparin (LMWH) are allowed

Study is for people with:

Kidney Cancer

Phase:

Phase 2

Estimated Enrollment:

200

Study ID:

NCT05411081

Recruitment Status:

Recruiting

Sponsor:

National Cancer Institute (NCI)

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 147 Locations for this study

See Locations Near You

Cancer Center at Saint Joseph's
Phoenix Arizona, 85004, United States More Info
Site Public Contact
Contact
720-874-1881
[email protected]
Shahzad Siddique
Principal Investigator
University of Arkansas for Medical Sciences
Little Rock Arkansas, 72205, United States More Info
Site Public Contact
Contact
501-686-8274
Shi-Ming Tu
Principal Investigator
Kaiser Permanente-Anaheim
Anaheim California, 92806, United States More Info
Site Public Contact
Contact
800-398-3996
[email protected]
Helen H. Moon
Principal Investigator
Kaiser Permanente-Baldwin Park
Baldwin Park California, 91706, United States More Info
Site Public Contact
Contact
800-398-3996
[email protected]
Helen H. Moon
Principal Investigator
Kaiser Permanente-Bellflower
Bellflower California, 90706, United States More Info
Site Public Contact
Contact
800-398-3996
[email protected]
Helen H. Moon
Principal Investigator
City of Hope Comprehensive Cancer Center
Duarte California, 91010, United States More Info
Site Public Contact
Contact
800-826-4673
[email protected]
Sumanta K. Pal
Principal Investigator
Epic Care-Dublin
Dublin California, 94568, United States More Info
Site Public Contact
Contact
925-875-1677
Lisa Bailey
Principal Investigator
Epic Care Partners in Cancer Care
Emeryville California, 94608, United States More Info
Site Public Contact
Contact
510-629-6682
Lisa Bailey
Principal Investigator
Kaiser Permanente-Fontana
Fontana California, 92335, United States More Info
Site Public Contact
Contact
800-398-3996
[email protected]
Helen H. Moon
Principal Investigator
Kaiser Permanente - Harbor City
Harbor City California, 90710, United States More Info
Site Public Contact
Contact
800-398-3996
[email protected]
Helen H. Moon
Principal Investigator
Kaiser Permanente-Irvine
Irvine California, 92618, United States More Info
Site Public Contact
Contact
800-398-3996
[email protected]
Helen H. Moon
Principal Investigator
Kaiser Permanente Los Angeles Medical Center
Los Angeles California, 90027, United States More Info
Site Public Contact
Contact
800-398-3996
[email protected]
Helen H. Moon
Principal Investigator
Kaiser Permanente West Los Angeles
Los Angeles California, 90034, United States More Info
Site Public Contact
Contact
800-398-3996
[email protected]
Helen H. Moon
Principal Investigator
Contra Costa Regional Medical Center
Martinez California, 94553, United States More Info
Site Public Contact
Contact
925-957-5400
Lisa Bailey
Principal Investigator
Kaiser Permanente-Ontario
Ontario California, 91761, United States More Info
Site Public Contact
Contact
800-398-3996
[email protected]
Helen H. Moon
Principal Investigator
Kaiser Permanente - Panorama City
Panorama City California, 91402, United States More Info
Site Public Contact
Contact
800-398-3996
[email protected]
Helen H. Moon
Principal Investigator
Kaiser Permanente-Riverside
Riverside California, 92505, United States More Info
Site Public Contact
Contact
800-398-3996
[email protected]
Helen H. Moon
Principal Investigator
University of California Davis Comprehensive Cancer Center
Sacramento California, 95817, United States More Info
Site Public Contact
Contact
916-734-3089
Shuchi Gulati
Principal Investigator
Kaiser Permanente-San Diego Zion
San Diego California, 92120, United States More Info
Site Public Contact
Contact
800-398-3996
[email protected]
Helen H. Moon
Principal Investigator
Kaiser Permanente-San Marcos
San Marcos California, 92078, United States More Info
Site Public Contact
Contact
800-398-3996
[email protected]
Helen H. Moon
Principal Investigator
Epic Care Cyberknife Center
Walnut Creek California, 94597, United States More Info
Site Public Contact
Contact
510-465-8016
[email protected]
Lisa Bailey
Principal Investigator
Kaiser Permanente-Woodland Hills
Woodland Hills California, 91367, United States More Info
Site Public Contact
Contact
800-398-3996
[email protected]
Helen H. Moon
Principal Investigator
Saint Luke's Cancer Institute - Boise
Boise Idaho, 83712, United States More Info
Site Public Contact
Contact
208-381-2774
[email protected]
Charles W. Drescher
Principal Investigator
Saint Luke's Cancer Institute - Fruitland
Fruitland Idaho, 83619, United States More Info
Site Public Contact
Contact
208-381-2774
[email protected]
Charles W. Drescher
Principal Investigator
Saint Luke's Cancer Institute - Meridian
Meridian Idaho, 83642, United States More Info
Site Public Contact
Contact
208-381-2774
[email protected]
Charles W. Drescher
Principal Investigator
Saint Luke's Cancer Institute - Nampa
Nampa Idaho, 83686, United States More Info
Site Public Contact
Contact
208-381-2774
[email protected]
Charles W. Drescher
Principal Investigator
Saint Luke's Cancer Institute - Twin Falls
Twin Falls Idaho, 83301, United States More Info
Site Public Contact
Contact
208-381-2774
[email protected]
Charles W. Drescher
Principal Investigator
Illinois CancerCare-Bloomington
Bloomington Illinois, 61704, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Canton
Canton Illinois, 61520, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Carthage
Carthage Illinois, 62321, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Northwestern University
Chicago Illinois, 60611, United States More Info
Site Public Contact
Contact
312-695-1301
[email protected]
Niraj K. Shenoy
Principal Investigator
Carle at The Riverfront
Danville Illinois, 61832, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Vamsi K. Vasireddy
Principal Investigator
Cancer Care Specialists of Illinois - Decatur
Decatur Illinois, 62526, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Decatur Memorial Hospital
Decatur Illinois, 62526, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Northwestern Medicine Cancer Center Kishwaukee
DeKalb Illinois, 60115, United States More Info
Site Public Contact
Contact
630-352-5360
[email protected]
Niraj K. Shenoy
Principal Investigator
Illinois CancerCare-Dixon
Dixon Illinois, 61021, United States More Info
Site Public Contact
Contact
815-285-7800
Bryan A. Faller
Principal Investigator
Carle Physician Group-Effingham
Effingham Illinois, 62401, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Vamsi K. Vasireddy
Principal Investigator
Crossroads Cancer Center
Effingham Illinois, 62401, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Eureka
Eureka Illinois, 61530, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Galesburg
Galesburg Illinois, 61401, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Northwestern Medicine Cancer Center Delnor
Geneva Illinois, 60134, United States More Info
Site Public Contact
Contact
630-352-5360
[email protected]
Niraj K. Shenoy
Principal Investigator
Northwestern Medicine Glenview Outpatient Center
Glenview Illinois, 60026, United States More Info
Site Public Contact
Contact
312-695-1102
Niraj K. Shenoy
Principal Investigator
Northwestern Medicine Grayslake Outpatient Center
Grayslake Illinois, 60030, United States More Info
Site Public Contact
Contact
312-695-1102
Niraj K. Shenoy
Principal Investigator
Illinois CancerCare-Kewanee Clinic
Kewanee Illinois, 61443, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Northwestern Medicine Lake Forest Hospital
Lake Forest Illinois, 60045, United States More Info
Site Public Contact
Contact
[email protected]
Niraj K. Shenoy
Principal Investigator
Illinois CancerCare-Macomb
Macomb Illinois, 61455, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Carle Physician Group-Mattoon/Charleston
Mattoon Illinois, 61938, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Vamsi K. Vasireddy
Principal Investigator
Loyola University Medical Center
Maywood Illinois, 60153, United States More Info
Site Public Contact
Contact
708-226-4357
Joseph I. Clark
Principal Investigator
Cancer Care Center of O'Fallon
O'Fallon Illinois, 62269, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Northwestern Medicine Orland Park
Orland Park Illinois, 60462, United States More Info
Site Public Contact
Contact
[email protected]
Niraj K. Shenoy
Principal Investigator
Illinois CancerCare-Ottawa Clinic
Ottawa Illinois, 61350, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Pekin
Pekin Illinois, 61554, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Peoria
Peoria Illinois, 61615, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Peru
Peru Illinois, 61354, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Princeton
Princeton Illinois, 61356, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Southern Illinois University School of Medicine
Springfield Illinois, 62702, United States More Info
Site Public Contact
Contact
217-545-7929
Bryan A. Faller
Principal Investigator
Springfield Clinic
Springfield Illinois, 62702, United States More Info
Site Public Contact
Contact
800-444-7541
Bryan A. Faller
Principal Investigator
Memorial Medical Center
Springfield Illinois, 62781, United States More Info
Site Public Contact
Contact
217-528-7541
[email protected]
Bryan A. Faller
Principal Investigator
Carle Cancer Center
Urbana Illinois, 61801, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Vamsi K. Vasireddy
Principal Investigator
Northwestern Medicine Cancer Center Warrenville
Warrenville Illinois, 60555, United States More Info
Site Public Contact
Contact
630-352-5360
[email protected]
Niraj K. Shenoy
Principal Investigator
Illinois CancerCare - Washington
Washington Illinois, 61571, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Mary Greeley Medical Center
Ames Iowa, 50010, United States More Info
Site Public Contact
Contact
515-956-4132
Joseph J. Merchant
Principal Investigator
McFarland Clinic - Ames
Ames Iowa, 50010, United States More Info
Site Public Contact
Contact
515-239-4734
[email protected]
Joseph J. Merchant
Principal Investigator
McFarland Clinic - Boone
Boone Iowa, 50036, United States More Info
Site Public Contact
Contact
515-956-4132
Joseph J. Merchant
Principal Investigator
Mercy Medical Center - Des Moines
Des Moines Iowa, 50314, United States More Info
Site Public Contact
Contact
515-358-6613
[email protected]
Richard L. Deming
Principal Investigator
McFarland Clinic - Trinity Cancer Center
Fort Dodge Iowa, 50501, United States More Info
Site Public Contact
Contact
515-956-4132
Joseph J. Merchant
Principal Investigator
McFarland Clinic - Jefferson
Jefferson Iowa, 50129, United States More Info
Site Public Contact
Contact
515-956-4132
Joseph J. Merchant
Principal Investigator
McFarland Clinic - Marshalltown
Marshalltown Iowa, 50158, United States More Info
Site Public Contact
Contact
515-956-4132
Joseph J. Merchant
Principal Investigator
Cotton O'Neil Cancer Center / Stormont Vail Health
Topeka Kansas, 66606, United States More Info
Site Public Contact
Contact
785-270-4939
Brandon R. Weckbaugh
Principal Investigator
East Jefferson General Hospital
Metairie Louisiana, 70006, United States More Info
Site Public Contact
Contact
504-210-3539
[email protected]
Carrie Marquette
Principal Investigator
LSU Healthcare Network / Metairie Multi-Specialty Clinic
Metairie Louisiana, 70006, United States More Info
Site Public Contact
Contact
504-210-3539
[email protected]
Carrie Marquette
Principal Investigator
University Medical Center New Orleans
New Orleans Louisiana, 70112, United States More Info
Site Public Contact
Contact
504-210-3539
[email protected]
Carrie Marquette
Principal Investigator
Touro Infirmary
New Orleans Louisiana, 70115, United States More Info
Site Public Contact
Contact
504-210-3539
[email protected]
Carrie Marquette
Principal Investigator
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore Maryland, 21287, United States More Info
Site Public Contact
Contact
410-955-8804
[email protected]
Yasser Ged
Principal Investigator
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Ann Arbor Michigan, 48106, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Tareq Al Baghdadi
Principal Investigator
Bronson Battle Creek
Battle Creek Michigan, 49017, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton Michigan, 48114, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Tareq Al Baghdadi
Principal Investigator
Trinity Health Medical Center - Brighton
Brighton Michigan, 48114, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Tareq Al Baghdadi
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton Michigan, 48188, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Tareq Al Baghdadi
Principal Investigator
Trinity Health Medical Center - Canton
Canton Michigan, 48188, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Tareq Al Baghdadi
Principal Investigator
Caro Cancer Center
Caro Michigan, 48723, United States More Info
Site Public Contact
Contact
989-907-8411
[email protected]
Tareq Al Baghdadi
Principal Investigator
Saint Joseph Mercy Chelsea
Chelsea Michigan, 48118, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Tareq Al Baghdadi
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea Michigan, 48118, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Tareq Al Baghdadi
Principal Investigator
Wayne State University/Karmanos Cancer Institute
Detroit Michigan, 48201, United States More Info
Site Public Contact
Contact
313-576-9790
[email protected]
Elisabeth I. Heath
Principal Investigator
Weisberg Cancer Treatment Center
Farmington Hills Michigan, 48334, United States More Info
Site Public Contact
Contact
313-576-9790
[email protected]
Elisabeth I. Heath
Principal Investigator
Genesee Cancer and Blood Disease Treatment Center
Flint Michigan, 48503, United States More Info
Site Public Contact
Contact
810-762-8038
[email protected]
Tareq Al Baghdadi
Principal Investigator
Genesee Hematology Oncology PC
Flint Michigan, 48503, United States More Info
Site Public Contact
Contact
810-762-8038
[email protected]
Tareq Al Baghdadi
Principal Investigator
Genesys Hurley Cancer Institute
Flint Michigan, 48503, United States More Info
Site Public Contact
Contact
810-762-8038
[email protected]
Tareq Al Baghdadi
Principal Investigator
Hurley Medical Center
Flint Michigan, 48503, United States More Info
Site Public Contact
Contact
810-762-8038
[email protected]
Tareq Al Baghdadi
Principal Investigator
Corewell Health Grand Rapids Hospitals - Butterworth Hospital
Grand Rapids Michigan, 49503, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Bronson Methodist Hospital
Kalamazoo Michigan, 49007, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
West Michigan Cancer Center
Kalamazoo Michigan, 49007, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Ascension Borgess Cancer Center
Kalamazoo Michigan, 49009, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
University of Michigan Health - Sparrow Lansing
Lansing Michigan, 48912, United States More Info
Site Public Contact
Contact
517-364-3712
[email protected]
Tareq Al Baghdadi
Principal Investigator
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia Michigan, 48154, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Tareq Al Baghdadi
Principal Investigator
Saint Mary's Oncology/Hematology Associates of Marlette
Marlette Michigan, 48453, United States More Info
Site Public Contact
Contact
989-907-8411
[email protected]
Tareq Al Baghdadi
Principal Investigator
Trinity Health Muskegon Hospital
Muskegon Michigan, 49444, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Cancer and Hematology Centers of Western Michigan - Norton Shores
Norton Shores Michigan, 49444, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Ascension Saint Mary's Hospital
Saginaw Michigan, 48601, United States More Info
Site Public Contact
Contact
989-907-8411
[email protected]
Tareq Al Baghdadi
Principal Investigator
Oncology Hematology Associates of Saginaw Valley PC
Saginaw Michigan, 48604, United States More Info
Site Public Contact
Contact
989-907-8411
[email protected]
Tareq Al Baghdadi
Principal Investigator
Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
Saint Joseph Michigan, 49085, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Ascension Saint Joseph Hospital
Tawas City Michigan, 48764, United States More Info
Site Public Contact
Contact
989-907-8411
[email protected]
Tareq Al Baghdadi
Principal Investigator
Munson Medical Center
Traverse City Michigan, 49684, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Saint Mary's Oncology/Hematology Associates of West Branch
West Branch Michigan, 48661, United States More Info
Site Public Contact
Contact
989-907-8411
[email protected]
Tareq Al Baghdadi
Principal Investigator
University of Michigan Health - West
Wyoming Michigan, 49519, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Huron Gastroenterology PC
Ypsilanti Michigan, 48106, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Tareq Al Baghdadi
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti Michigan, 48197, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Tareq Al Baghdadi
Principal Investigator
Mercy Hospital
Coon Rapids Minnesota, 55433, United States More Info
Site Public Contact
Contact
952-993-1517
[email protected]
David M. King
Principal Investigator
Fairview Southdale Hospital
Edina Minnesota, 55435, United States More Info
Site Public Contact
Contact
952-993-1517
[email protected]
David M. King
Principal Investigator
Saint John's Hospital - Healtheast
Maplewood Minnesota, 55109, United States More Info
Site Public Contact
Contact
952-993-1517
[email protected]
David M. King
Principal Investigator
Abbott-Northwestern Hospital
Minneapolis Minnesota, 55407, United States More Info
Site Public Contact
Contact
952-993-1517
[email protected]
David M. King
Principal Investigator
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park Minnesota, 55416, United States More Info
Site Public Contact
Contact
952-993-1517
[email protected]
David M. King
Principal Investigator
Regions Hospital
Saint Paul Minnesota, 55101, United States More Info
Site Public Contact
Contact
952-993-1517
[email protected]
David M. King
Principal Investigator
United Hospital
Saint Paul Minnesota, 55102, United States More Info
Site Public Contact
Contact
952-993-1517
[email protected]
David M. King
Principal Investigator
University of Mississippi Medical Center
Jackson Mississippi, 39216, United States More Info
Site Public Contact
Contact
601-815-6700
John C. Henegan
Principal Investigator
Saint Francis Medical Center
Cape Girardeau Missouri, 63703, United States More Info
Site Public Contact
Contact
573-334-2230
[email protected]
Bryan A. Faller
Principal Investigator
Parkland Health Center - Farmington
Farmington Missouri, 63640, United States More Info
Site Public Contact
Contact
314-996-5569
Bryan A. Faller
Principal Investigator
Missouri Baptist Medical Center
Saint Louis Missouri, 63131, United States More Info
Site Public Contact
Contact
314-996-5569
Bryan A. Faller
Principal Investigator
Sainte Genevieve County Memorial Hospital
Sainte Genevieve Missouri, 63670, United States More Info
Site Public Contact
Contact
314-996-5569
Bryan A. Faller
Principal Investigator
Missouri Baptist Sullivan Hospital
Sullivan Missouri, 63080, United States More Info
Site Public Contact
Contact
314-996-5569
Bryan A. Faller
Principal Investigator
BJC Outpatient Center at Sunset Hills
Sunset Hills Missouri, 63127, United States More Info
Site Public Contact
Contact
314-996-5569
Bryan A. Faller
Principal Investigator
Hackensack University Medical Center
Hackensack New Jersey, 07601, United States More Info
Site Public Contact
Contact
201-996-2879
Robert S. Alter
Principal Investigator
Duke Cancer Institute Cary
Cary North Carolina, 27518, United States More Info
Site Public Contact
Contact
919-781-7070
Michael R. Harrison
Principal Investigator
Southeastern Medical Oncology Center-Clinton
Clinton North Carolina, 28328, United States More Info
Site Public Contact
Contact
919-587-9084
[email protected]
Samer S. Kasbari
Principal Investigator
Duke University Medical Center
Durham North Carolina, 27710, United States More Info
Site Public Contact
Contact
888-275-3853
Michael R. Harrison
Principal Investigator
Southeastern Medical Oncology Center-Goldsboro
Goldsboro North Carolina, 27534, United States More Info
Site Public Contact
Contact
919-587-9084
[email protected]
Samer S. Kasbari
Principal Investigator
Southeastern Medical Oncology Center-Jacksonville
Jacksonville North Carolina, 28546, United States More Info
Site Public Contact
Contact
910-587-9084
[email protected]
Samer S. Kasbari
Principal Investigator
FirstHealth of the Carolinas-Moore Regional Hospital
Pinehurst North Carolina, 28374, United States More Info
Site Public Contact
Contact
910-715-3500
[email protected]
Charles S. Kuzma
Principal Investigator
Duke Raleigh Hospital
Raleigh North Carolina, 27609, United States More Info
Site Public Contact
Contact
919-862-5400
Michael R. Harrison
Principal Investigator
UH Seidman Cancer Center at UH Avon Health Center
Avon Ohio, 44011, United States
UHHS-Chagrin Highlands Medical Center
Beachwood Ohio, 44122, United States
Miami Valley Hospital South
Centerville Ohio, 45459, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Tarek M. Sabagh
Principal Investigator
Case Western Reserve University
Cleveland Ohio, 44106, United States
Miami Valley Hospital
Dayton Ohio, 45409, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Tarek M. Sabagh
Principal Investigator
Premier Blood and Cancer Center
Dayton Ohio, 45409, United States More Info
Site Public Contact
Contact
937-276-8320
Tarek M. Sabagh
Principal Investigator
Dayton Physician LLC - Englewood
Dayton Ohio, 45415, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Miami Valley Hospital North
Dayton Ohio, 45415, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Tarek M. Sabagh
Principal Investigator
Atrium Medical Center-Middletown Regional Hospital
Franklin Ohio, 45005, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Tarek M. Sabagh
Principal Investigator
Miami Valley Cancer Care and Infusion
Greenville Ohio, 45331, United States More Info
Site Public Contact
Contact
937-569-7515
Tarek M. Sabagh
Principal Investigator
Kettering Medical Center
Kettering Ohio, 45429, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Upper Valley Medical Center
Troy Ohio, 45373, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Tarek M. Sabagh
Principal Investigator
University of Oklahoma Health Sciences Center
Oklahoma City Oklahoma, 73104, United States More Info
Site Public Contact
Contact
405-271-8777
[email protected]
Adanma Anji Ayanambakkam Attanathi
Principal Investigator
Oklahoma Cancer Specialists and Research Institute-Tulsa
Tulsa Oklahoma, 74146, United States More Info
Site Public Contact
Contact
918-505-3200
Adanma Anji Ayanambakkam Attanathi
Principal Investigator
Providence Newberg Medical Center
Newberg Oregon, 97132, United States More Info
Site Public Contact
Contact
503-215-2614
[email protected]
Charles W. Drescher
Principal Investigator
Providence Willamette Falls Medical Center
Oregon City Oregon, 97045, United States More Info
Site Public Contact
Contact
503-215-2614
[email protected]
Charles W. Drescher
Principal Investigator
Providence Portland Medical Center
Portland Oregon, 97213, United States More Info
Site Public Contact
Contact
503-215-2614
[email protected]
Charles W. Drescher
Principal Investigator
Providence Saint Vincent Medical Center
Portland Oregon, 97225, United States More Info
Site Public Contact
Contact
503-215-2614
[email protected]
Charles W. Drescher
Principal Investigator
Oregon Health and Science University
Portland Oregon, 97239, United States More Info
Site Public Contact
Contact
503-494-1080
[email protected]
Christopher W. Ryan
Principal Investigator
UT Southwestern Simmons Cancer Center - RedBird
Dallas Texas, 75237, United States More Info
Site Public Contact
Contact
214-648-7097
[email protected]
Suzanne M. Cole
Principal Investigator
UT Southwestern/Simmons Cancer Center-Dallas
Dallas Texas, 75390, United States More Info
Site Public Contact
Contact
214-648-7097
[email protected]
Suzanne M. Cole
Principal Investigator
UT Southwestern/Simmons Cancer Center-Fort Worth
Fort Worth Texas, 76104, United States More Info
Site Public Contact
Contact
214-648-7097
[email protected]
Suzanne M. Cole
Principal Investigator
UT Southwestern Clinical Center at Richardson/Plano
Richardson Texas, 75080, United States More Info
Site Public Contact
Contact
972-669-7044
[email protected]
Suzanne M. Cole
Principal Investigator
University of Texas Health Science Center at San Antonio
San Antonio Texas, 78229, United States More Info
Site Public Contact
Contact
210-450-3800
[email protected]
Montaser Shaheen
Principal Investigator
Farmington Health Center
Farmington Utah, 84025, United States More Info
Site Public Contact
Contact
888-424-2100
[email protected]
Benjamin L. Maughan
Principal Investigator
Huntsman Cancer Institute/University of Utah
Salt Lake City Utah, 84112, United States More Info
Site Public Contact
Contact
888-424-2100
[email protected]
Benjamin L. Maughan
Principal Investigator
VCU Massey Cancer Center at Stony Point
Richmond Virginia, 23235, United States More Info
Site Public Contact
Contact
[email protected]
Asit K. Paul
Principal Investigator
Virginia Commonwealth University/Massey Cancer Center
Richmond Virginia, 23298, United States More Info
Site Public Contact
Contact
[email protected]
Asit K. Paul
Principal Investigator
Marshfield Medical Center-EC Cancer Center
Eau Claire Wisconsin, 54701, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Seth O. Fagbemi
Principal Investigator
Marshfield Medical Center-Marshfield
Marshfield Wisconsin, 54449, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Seth O. Fagbemi
Principal Investigator
Marshfield Clinic-Minocqua Center
Minocqua Wisconsin, 54548, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Seth O. Fagbemi
Principal Investigator
Marshfield Medical Center-Rice Lake
Rice Lake Wisconsin, 54868, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Seth O. Fagbemi
Principal Investigator
Marshfield Medical Center-River Region at Stevens Point
Stevens Point Wisconsin, 54482, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Seth O. Fagbemi
Principal Investigator
Marshfield Medical Center - Weston
Weston Wisconsin, 54476, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Seth O. Fagbemi
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Phase:

Phase 2

Estimated Enrollment:

200

Study ID:

NCT05411081

Recruitment Status:

Recruiting

Sponsor:


National Cancer Institute (NCI)

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.